Mirum Pharmaceuticals (MIRM) Price & Analysis

Compare

704 Followers

MIRM Stock Chart & Stats

$69.16

-$0.27(-0.64%)

At close: Jan 08 4:00 PM EST

$69.16

-$0.27(-0.64%)

Day’s Range― - ―

52-Week Range$36.88 - $78.54

Previous CloseN/A

Volume92.82K

Average Volume (3M)609.35K

Market Cap

$3.62B

Enterprise Value$4.12B

Total Cash (Recent Filing)$375.55M

Total Debt (Recent Filing)$318.76M

Price to Earnings (P/E)―

Beta0.71

Next Earnings

Mar 11, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.05

Shares Outstanding51,393,574

10 Day Avg. Volume667,564

30 Day Avg. Volume609,350

Financial Highlights & Ratios

PEG Ratio0.42

Price to Book (P/B)8.71

Price to Sales (P/S)5.83

P/FCF Ratio210.57

Enterprise Value/Market Cap1.14

Enterprise Value/Revenue8.74

Enterprise Value/Gross Profit10.93

Enterprise Value/Ebitda-751.40

Forecast

1Y Price Target

$88.11

Price Target Upside27.40% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-0.58

Revenue Forecast (FY)$506.38M

Bulls Say, Bears Say

Bulls Say

Intellectual Property DefenseManagement is confident in defending Livmarli’s intellectual property against expected generic filers.

Product Adoption And Pipeline PotentialLivmarli has seen favorable adoption across patient groups, and volixibat shows significant upside potential with exceeded efficacy and safety thresholds.

Sales And Revenue GrowthMirum Pharmaceuticals reported strong revenue growth, with Livmarli sales contributing significantly and exceeding expectations.

Bears Say

Generic CompetitionMirum received a Paragraph IV notification from Sandoz indicating an ANDA filing for a Livmarli generic, challenging existing patents.

Mirum Pharmaceuticals News

Mirum Pharmaceuticals price target raised to $95 from $85 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $85 and keeps an...

17d ago

MIRM

Mirum Pharmaceuticals price target raised to $81 from $80 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $81 from $80...

17d ago

MIRM

Mirum Pharmaceuticals price target raised to $95 from $81 at Citizens JMP

Citizens JMP raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $81 and keeps an...

17d ago

MIRM

Mirum Pharmaceuticals reports Q3 EPS 5c, consensus (16c)

Reports Q3 revenue $133.0M, consensus $130.5M. “Mirum is well positioned heading into 2026 with strong commercial momentum and...

17d ago

MIRM

Mirum Pharmaceuticals sees FY25 product sales of $500M-$510M, consensus $506.3M

17:02 EST Mirum Pharmaceuticals (MIRM) sees FY25 product sales of $500M-$510M, consensus $506.3M Published first on TheFly –...

17d ago

MIRM

Mirum Pharmaceuticals: Strategic Positioning and Strong Defense Justify Buy Rating

Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Mirum Pharmaceuticals and keeping the price target...

4d ago

MIRM

Mirum Pharmaceuticals Faces Patent Challenge from Sandoz

Mirum Pharmaceuticals ( ($MIRM) ) has issued an update. On November 17, 2025, Mirum Pharmaceuticals received a Paragraph...

4d ago

MIRM

Mirum Pharmaceuticals Reports Robust Q3 Growth and Milestones

Mirum Pharmaceuticals (($MIRM)) has held its Q3 earnings call. Read on for the main highlights of the call....

16d ago

MIRM

Mirum Pharmaceuticals Reports Strong Q3 2025 Growth

Mirum Pharmaceuticals ( ($MIRM) ) has released its Q3 earnings. Here is a breakdown of the information Mirum...

17d ago

MIRM

Mirum Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating

TD Cowen analyst Joseph Thome maintained a Buy rating on Mirum Pharmaceuticals yesterday and set a price target...

17d ago

MIRM

MIRM Upcoming Earnings Report: What to Expect?

Mirum Pharmaceuticals (MIRM) is scheduled to report 3rd quarter earnings on 11/04/2025, after the market closes. Regarding Q3...

20d ago

MIRM

Mirum Pharmaceuticals Advances in Fragile X Syndrome Treatment Study

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Study Overview: Mirum Pharmaceuticals is conducting a...

25d ago

MIRM

Mirum Pharmaceuticals’ Volixibat Study: A Potential Breakthrough for PBC Itching

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Study Overview: Mirum Pharmaceuticals is conducting a...

25d ago

MIRM

Mirum Pharmaceuticals Advances Phase 3 Study on Maralixibat for Cholestatic Pruritus

Mirum Pharmaceuticals (($MIRM)) announced an update on their ongoing clinical study. Mirum Pharmaceuticals is conducting a Phase 3...

25d ago

MIRM

MIRM FAQ

What was Mirum Pharmaceuticals Inc’s price range in the past 12 months?

Mirum Pharmaceuticals Inc lowest stock price was $36.88 and its highest was $78.54 in the past 12 months.

What is Mirum Pharmaceuticals Inc’s market cap?

Mirum Pharmaceuticals Inc’s market cap is $3.62B.

When is Mirum Pharmaceuticals Inc’s upcoming earnings report date?

Mirum Pharmaceuticals Inc’s upcoming earnings report date is Mar 11, 2026 which is in 109 days.

How were Mirum Pharmaceuticals Inc’s earnings last quarter?

Mirum Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.19.

Is Mirum Pharmaceuticals Inc overvalued?

According to Wall Street analysts Mirum Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mirum Pharmaceuticals Inc pay dividends?

Mirum Pharmaceuticals Inc does not currently pay dividends.

What is Mirum Pharmaceuticals Inc’s EPS estimate?

Mirum Pharmaceuticals Inc’s EPS estimate is -0.05.

How many shares outstanding does Mirum Pharmaceuticals Inc have?

Mirum Pharmaceuticals Inc has 51,393,574 shares outstanding.

What happened to Mirum Pharmaceuticals Inc’s price movement after its last earnings report?

Mirum Pharmaceuticals Inc reported an EPS of $0.05 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -1.24%.

Which hedge fund is a major shareholder of Mirum Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in MIRM

Mirum Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-15.81%

Trailing 12-Months

Asset Growth

17.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare liver diseases. The company is primarily engaged in the development of treatments that address unmet medical needs in the field of hepatology. Its core products include Maralixibat, a drug designed for the treatment of cholestatic liver diseases, and other candidates targeting various liver conditions.

Mirum Pharmaceuticals (MIRM) Earnings & Revenues

Historic Earnings Reports

MIRM Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Mirum Pharmaceuticals had a strong third quarter with significant revenue growth and positive net income for the first time. The company continues to advance its clinical pipeline and expand internationally. However, there are some challenges in revenue consistency and the adoption of genetic testing in certain segments.View all MIRM earnings summaries

MIRM Stock 12 Month Forecast

Average Price Target

$88.11

▲(27.40% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","96":"$96","53.25":"$53.3","67.5":"$67.5","81.75":"$81.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$77.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,53.25,67.5,81.75,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.65,74.36923076923077,76.08846153846154,77.8076923076923,79.52692307692308,81.24615384615385,82.96538461538462,84.68461538461538,86.40384615384616,88.12307692307692,89.8423076923077,91.56153846153846,93.28076923076924,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.65,73.83923076923078,75.02846153846154,76.21769230769232,77.40692307692308,78.59615384615385,79.78538461538461,80.97461538461539,82.16384615384615,83.35307692307693,84.54230769230769,85.73153846153846,86.92076923076922,{"y":88.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,72.65,72.9846153846154,73.31923076923077,73.65384615384616,73.98846153846154,74.32307692307693,74.65769230769232,74.99230769230769,75.32692307692308,75.66153846153847,75.99615384615385,76.33076923076923,76.66538461538461,{"y":77,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.4,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.42,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.39,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.65,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >